Labels:dialog box | monitor | sky | window OCR: NICE Safety of Enoxaparin Therapy in Patients Undergoing PCI and Receiving Concomitant Abciximab Therapy Open label multicenter 817 patients PC with FDA approved device Enoxaparin 75 mg/kg I.V bolus followed by abciximab 25 mg/kg bolus and 24 mcg/kg/min infusion (to max 10 mcg/min Criteria evaluatior major hemorinage/transtusior Findings enoxaparin abciximab not result in more bleeding compared with historical controls patients undergoing PC Kereiakes, etal.Inva Cardiol 200012:1A -54 evaluation hemorrhage transfusion 2000
(.png)
